JP2011516467A - Anti-peptic ulcer composition containing rice prolamin - Google Patents

Anti-peptic ulcer composition containing rice prolamin Download PDF

Info

Publication number
JP2011516467A
JP2011516467A JP2011502850A JP2011502850A JP2011516467A JP 2011516467 A JP2011516467 A JP 2011516467A JP 2011502850 A JP2011502850 A JP 2011502850A JP 2011502850 A JP2011502850 A JP 2011502850A JP 2011516467 A JP2011516467 A JP 2011516467A
Authority
JP
Japan
Prior art keywords
glutinous rice
peptic ulcer
extract
prolamin
fraction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2011502850A
Other languages
Japanese (ja)
Inventor
ボンファン アン,
ドンオプ ソン,
ミソン ジャン,
ヨンド ジョン,
ソンリョル ヤン,
ギオ チェ,
ブアン シン,
Original Assignee
ダサン エムアンドエフ,アイエヌシー.
インダストリー ファウンデーション オブ チョンナム ナショナル ユニバーシティー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ダサン エムアンドエフ,アイエヌシー., インダストリー ファウンデーション オブ チョンナム ナショナル ユニバーシティー filed Critical ダサン エムアンドエフ,アイエヌシー.
Publication of JP2011516467A publication Critical patent/JP2011516467A/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/195Carboxylic acids, e.g. valproic acid having an amino group
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/3533,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/25Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258Panax (ginseng)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/185Magnoliopsida (dicotyledons)
    • A61K36/82Theaceae (Tea family), e.g. camellia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18Magnoliophyta (angiosperms)
    • A61K36/88Liliopsida (monocotyledons)
    • A61K36/899Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
    • A61K36/8998Hordeum (barley)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

本発明は、米プロラミンを活性成分として含むことを特徴とする抗消化性潰瘍組成物に関するものである。本発明の抗消化性潰瘍組成物は、消化性潰瘍において卓越した予防または治療効果を有し、かつ一般食品の蛋白質を活性成分として含むことから安全性が高いので、広範囲に利用できる。  The present invention relates to an anti-peptic ulcer composition comprising rice prolamin as an active ingredient. The anti-peptic ulcer composition of the present invention has an excellent preventive or therapeutic effect in peptic ulcer, and since it contains a protein of general food as an active ingredient, it can be used in a wide range.

Description

本発明は、米プロラミンを活性成分として含む抗消化性潰瘍組成物に関し、それは茶抽出物、水参抽出物、大麦抽出物、(‐)‐エピカテキン(EC)、タンニン酸およびシステインからなる群より選択される少なくとも1種を、米プロラミンの活性促進用の補助成分として更に含む。   The present invention relates to an anti-peptic ulcer composition containing rice prolamin as an active ingredient, which comprises a tea extract, a water extract, a barley extract, (-)-epicatechin (EC), tannic acid and cysteine At least one selected from the above is further included as an auxiliary component for promoting the activity of rice prolamin.

消化性潰瘍に対する薬物治療の主な目的は、痛みを解消し、潰瘍自体を治癒し、そして潰瘍の再発と合併症を予防することにある。このために、一般に制酸剤、H2‐受容体拮抗薬、プロトンポンプ阻害薬、抗ヘリコバクターピロリ剤(anti-Helicobacter pylori preparations)等の様々な種類の薬物が使用されている。しかしながら、これら薬物を長期にわたって常用すると、様々な副作用をおこしうるため、注意を要する。 The main purpose of drug treatment for peptic ulcer is to relieve pain, heal the ulcer itself, and prevent recurrence and complications of the ulcer. For this purpose, various kinds of drugs such as antacids, H 2 -receptor antagonists, proton pump inhibitors, anti-Helicobacter pylori preparations are generally used. However, if these drugs are used regularly over a long period, various side effects may occur, so care must be taken.

また、本発明者等は、もち米抽出物が非常に効果的に胃潰瘍の発生を抑制し、そして発生した潰瘍の治癒に卓越した効果があるだけでなく、一般食品由来のものであることから安全性が高いということを報告している(韓国特許第0208969号、第0253740号および第10-0627820号)。しかし、前記の特許ではもち米抽出物中に存在する、抗消化性潰瘍活性を有する主要な物質が明らかにされなかった。   In addition, the inventors of the present invention not only have a glutinous rice extract that effectively suppresses the occurrence of gastric ulcer and has an excellent effect on healing of the generated ulcer, but also derived from general foods. It is reported that the safety is high (Korea patents 0208969, 0253740 and 10-0627820). However, the above patents did not reveal the main substance with anti-peptic ulcer activity present in glutinous rice extract.

韓国特許第0208969号公報Korean Patent No. 0208969 韓国特許第0253740号公報Korean Patent No. 0253740 韓国特許第10-0627820号公報Korean Patent No. 10-0627820

本発明者等は、もち米抽出物中の抗消化性潰瘍活性を有する物質を明らかにするために研究を重ねた結果、米プロラミンがこのような活性を有することを見出し、本発明を完成させた。   As a result of repeated studies to clarify a substance having anti-peptic ulcer activity in glutinous rice extract, the present inventors have found that rice prolamin has such an activity, and completed the present invention. It was.

本発明は、米プロラミンを活性成分として含むことを特徴とする抗消化性潰瘍組成物を提供する。   The present invention provides an anti-peptic ulcer composition comprising rice prolamin as an active ingredient.

また、本発明者らは、米プロラミンを活性成分として含む組成物に、茶抽出物、水参抽出物、大麦抽出物、(‐)‐エピカテキン(epicatechin)、タンニン酸およびシステインからなる群より選択される少なくとも1種を補助成分として更に含ませることにより、その効果が上昇することを見出した。このような補助成分は、米プロラミン1重量部に対して1〜80重量部の量で含まれることが好ましい。   In addition, the inventors of the present invention include a composition comprising rice prolamin as an active ingredient, from the group consisting of tea extract, water extract, barley extract, (−)-epicatechin, tannic acid and cysteine. It has been found that the effect is enhanced by further including at least one selected component as an auxiliary component. Such an auxiliary component is preferably contained in an amount of 1 to 80 parts by weight based on 1 part by weight of rice prolamin.

本発明の抗消化性潰瘍組成物の活性成分である米プロラミンは、もち米またはうるち米から精製でき、米プロラミンと類似の構造を有するプロラミン誘導体も使用できる。本発明の組成物は、経口投与用製剤に製剤化でき、また薬剤学的に許容可能な担体を含有できる。   Rice prolamin which is an active ingredient of the anti-peptic ulcer composition of the present invention can be purified from glutinous rice or glutinous rice, and prolamin derivatives having a structure similar to rice prolamin can also be used. The composition of the present invention can be formulated into preparations for oral administration and can contain a pharmaceutically acceptable carrier.

この組成物の1回の服用量は、体重1Kg当りもち米プロラミン0.3〜3mgであることが好ましく、1日1〜10回の服用が推奨される。   The dosage of this composition is preferably 0.3 to 3 mg of glutinous rice prolamin per kg body weight, and 1 to 10 times a day is recommended.

米プロラミンを活性成分として含む本発明の組成物は、消化性潰瘍において優れた予防および治療効果を有する。   The composition of the present invention containing rice prolamin as an active ingredient has excellent preventive and therapeutic effects in peptic ulcer.

図1は、もち米抽出物、うるち米抽出物、大麦抽出物および小麦抽出物の抗消化性潰瘍活性を示す。FIG. 1 shows the anti-peptic ulcer activity of glutinous rice extract, glutinous rice extract, barley extract and wheat extract. 図2は、もち米抽出物全体、もち米抽出物の沈殿分画、及びもち米抽出物の可溶分画の抗消化性潰瘍活性を示す。FIG. 2 shows the anti-peptic ulcer activity of the whole glutinous rice extract, the precipitated fraction of the glutinous rice extract, and the soluble fraction of the glutinous rice extract. 図3は、もち米抽出物の沈殿分画を100℃で5分間加熱処理するか、またはペプシン処理した場合の抗消化性潰瘍活性の変化を表したものである。FIG. 3 shows the change in anti-peptic ulcer activity when the precipitate fraction of glutinous rice extract is heat-treated at 100 ° C. for 5 minutes or treated with pepsin. 図4は、もち米抽出物の沈殿分画をそれぞれ0.5M NaCl、1%乳酸、及び70%エタノールで抽出したときの、可溶化亜分画(solubilized subfraction)と残留沈殿分画とにおける抗消化性潰瘍活性の分布を表したものである。Figure 4 shows the anti-digestion of the solubilized subfraction and the residual precipitate fraction when the precipitated fraction of glutinous rice extract was extracted with 0.5M NaCl, 1% lactic acid, and 70% ethanol, respectively. It shows the distribution of sexual ulcer activity. 図5は、もち米から精製したプロラミンのSDS-PAGE分析を図示したものである。FIG. 5 shows an SDS-PAGE analysis of prolamin purified from glutinous rice. 図6は、もち米から精製したプロラミンの用量依存性の抗消化性潰瘍活性を表したものである。FIG. 6 shows the dose-dependent anti-peptic ulcer activity of prolamin purified from glutinous rice. 図7は、うるち米から精製したプロラミンのSDS-PAGE分析を図示したものである。FIG. 7 shows an SDS-PAGE analysis of prolamin purified from glutinous rice. 図8は、うるち米から精製したプロラミンの用量依存性の抗消化性潰瘍活性を表したものである。FIG. 8 shows the dose-dependent anti-peptic ulcer activity of prolamin purified from glutinous rice.

このように本発明の様々な側面を説明してきたが、以下、本発明の具体的態様を下記の実施例および実験例にて説明する。但し、本発明の範囲がこれらによって限定されるものではない。   While various aspects of the present invention have been described above, specific embodiments of the present invention will be described in the following examples and experimental examples. However, the scope of the present invention is not limited by these.

[実施例1]:もち米抽出物の調製
もち米粉末150gを5倍重量の蒸留水に加え、ボルテックスミキサーを用いて30秒間3回激しく攪拌した。撹拌後、混合液を3,000×gで10分間遠心分離して上清を得た。米国のピアス(Pierce)社製BCAキットを用いて測定した前記上清の蛋白濃度は、1.42mg/mlだった。この上清を蒸留水で希釈して蛋白濃度が1mg/mlになるようにし、これをもち米抽出物として使用した。
[Example 1]: Preparation of glutinous rice extract 150 g of glutinous rice powder was added to 5 times weight of distilled water, and vigorously stirred three times for 30 seconds using a vortex mixer. After stirring, the mixture was centrifuged at 3,000 × g for 10 minutes to obtain a supernatant. The protein concentration of the supernatant measured using a Pierce BCA kit in the United States was 1.42 mg / ml. The supernatant was diluted with distilled water to a protein concentration of 1 mg / ml, and this was used as a glutinous rice extract.

[実施例2]:もち米抽出物の沈殿分画および可溶分画の調製
実施例1で調製したもち米抽出物500mlを室温で15時間放置して沈殿を形成させ、2,000×gで10分間遠心分離した。得られた沈殿物を500mlの蒸留水に懸濁させて、これをもち米抽出物の沈殿分画として使用した。そして、澄んだ上清をもち米抽出物の可溶分画として使用した。
[Example 2]: Preparation of precipitate fraction and soluble fraction of glutinous rice extract 500 ml of glutinous rice extract prepared in Example 1 was allowed to stand at room temperature for 15 hours to form a precipitate. Centrifuged for minutes. The obtained precipitate was suspended in 500 ml of distilled water and used as a precipitate fraction of the glutinous rice extract. The clear supernatant was used as the soluble fraction of glutinous rice extract.

[実施例3]:うるち米抽出物とその可溶分画の調製
実施例1及び2と同様の方法でうるち米抽出物およびその可溶分画を調製した。うるち米粉末50gを5倍重量の蒸留水に加え、ボルテックスミキサーを用いて30秒間3回激しく撹拌した。撹拌後、混合液を3,000×gで10分間遠心分離して上清を得て、それを蛋白濃度が1mg/mlになるように希釈して、これをうるち米抽出物として使用した。うるち米抽出物を室温で15時間放置して沈殿を形成させた後、2,000×gで10分間遠心分離して澄んだ上清を得て、これをうるち米抽出物の可溶分画として使用した。
[Example 3]: Preparation of glutinous rice extract and its soluble fraction A glutinous rice extract and its soluble fraction were prepared in the same manner as in Examples 1 and 2. 50 g of glutinous rice powder was added to 5 times the weight of distilled water and vigorously stirred three times for 30 seconds using a vortex mixer. After stirring, the mixture was centrifuged at 3,000 × g for 10 minutes to obtain a supernatant, which was diluted to a protein concentration of 1 mg / ml, and used as a glutinous rice extract. The glutinous rice extract was allowed to stand at room temperature for 15 hours to form a precipitate, and then centrifuged at 2,000 × g for 10 minutes to obtain a clear supernatant, which was used as a soluble fraction of the glutinous rice extract.

[実施例4]:大麦抽出物および小麦抽出物とそれらの可溶分画の調製
大麦および小麦粉末それぞれ50gを5倍重量の蒸留水に加え、ボルテックスミキサーを使用して30秒間3回激しく攪拌した。撹拌後、混合液を3,000×gで10分間遠心分離して上清を得た。これら上清を蛋白濃度が1mg/mlになるように希釈して、それぞれ大麦抽出物および小麦抽出物として使用した。必要により、これらの抽出物を15,000×gで20分間遠心して、得られた澄んだ上清を、大麦抽出物および小麦抽出物の可溶分画として使用した。
[Example 4]: Preparation of barley extract and wheat extract and their soluble fractions 50 g each of barley and wheat flour was added to 5 times weight of distilled water and vigorously stirred three times for 30 seconds using a vortex mixer did. After stirring, the mixture was centrifuged at 3,000 × g for 10 minutes to obtain a supernatant. These supernatants were diluted to a protein concentration of 1 mg / ml and used as barley extract and wheat extract, respectively. If necessary, these extracts were centrifuged at 15,000 × g for 20 minutes, and the resulting clear supernatant was used as a soluble fraction of barley and wheat extracts.

[実施例5]:水参抽出物の可溶分画の調製
水参25gを10倍重量の蒸留水に加え、ボルテックスミキサーを用いて30秒間3回激しく攪拌した。撹拌後、混合液を15,000×gで20分間遠心分離して、得られた澄んだ上清を、水参抽出物の可溶分画として使用した。
[Example 5]: Preparation of soluble fraction of water extract Extract 25 g of water extract was added to 10 times weight of distilled water, and vigorously stirred 3 times for 30 seconds using a vortex mixer. After stirring, the mixture was centrifuged at 15,000 × g for 20 minutes, and the resulting clear supernatant was used as the soluble fraction of the water extract.

[実施例6]:茶抽出物の可溶分画の調製
緑茶(韓国のアモレパシフィック社、商品名:ハンラ)、紅茶(英国のLipton社製)、烏龍茶(中国福建省産)を10gずつそれぞれ100倍重量の沸騰した蒸留水に入れて10分間抽出し、ろ過した。この検討において、このろ液をそのまま、または凍結乾燥させて使用した。
[Example 6]: Preparation of soluble fraction of tea extract 10g each of green tea (Amore Pacific, Korea, trade name: Hanra), black tea (Lipton, UK), and oolong tea (Fujian, China) It was extracted for 10 minutes in boiling water with 100 times weight and filtered. In this examination, this filtrate was used as it was or freeze-dried.

[実施例7]:米プロラミンの精製
もち米またはうるち米粉末100gを蒸留水300mlで4時間抽出し、2,000×gで10分間遠心分離して上清を除去した。以上のような抽出過程を1度繰り返した。その後、得られた沈殿物を300mlの0.5M NaClで4時間、2回抽出した。このようにして得られた沈殿物を300mlの2−プロパノールで1時間抽出し、当該抽出を1回繰り返した。2つのプロパノール抽出液をためてろ過し、フード(hood)中で乾燥させた。
[Example 7]: Purification of rice prolamin 100 g of glutinous rice or glutinous rice powder was extracted with 300 ml of distilled water for 4 hours, and centrifuged at 2,000 xg for 10 minutes to remove the supernatant. The above extraction process was repeated once. The resulting precipitate was then extracted twice with 300 ml of 0.5M NaCl for 4 hours. The precipitate thus obtained was extracted with 300 ml of 2-propanol for 1 hour, and the extraction was repeated once. Two propanol extracts were collected and dried in a hood.

前記乾燥物を50mlの70%エタノールに溶かし、ろ過した。そして、ろ液に3容量の氷冷アセトンをゆっくり加えて蛋白沈殿を形成させ、そして2,000×gで20分間遠心分離した。このようにして得られた沈殿物を30mlの70%エタノールに溶かし、ろ過し、そして3容量の氷冷アセトンに加えて蛋白沈殿を形成させた。そしてこの過程を1回繰り返した。得られた蛋白沈殿を蒸留水で24時間透析した。最終的に、62mgのもち米プロラミンと85mgのうるち米プロラミンを得た。   The dried product was dissolved in 50 ml of 70% ethanol and filtered. The filtrate was then slowly added with 3 volumes of ice-cold acetone to form a protein precipitate and centrifuged at 2,000 × g for 20 minutes. The precipitate thus obtained was dissolved in 30 ml of 70% ethanol, filtered and added to 3 volumes of ice-cold acetone to form a protein precipitate. This process was repeated once. The obtained protein precipitate was dialyzed against distilled water for 24 hours. Finally, 62 mg of glutinous rice prolamin and 85 mg of glutinous rice prolamin were obtained.

実験例1:米抽出物中に存在する抗消化性潰瘍性物質の同定
(1) 抗消化性潰瘍活性の測定
Yamasaki等(Eur. J. Pharmacol. 142, 23-29, 1987)に記述された方法に少し変更を加えて測定を行った。体重250±20gの雄性ラット(Sprague-Dawley)にエタノール1mlを経口投与し、胃潰瘍を誘発させた。抗消化性潰瘍調製物の活性を測定するために、エタノール投与の30分前に試験調製物1mlを経口投与した。対照群には、同量の蒸留水を投与した。エタノール投与1.5時間後にエーテル麻酔下でラットを屠殺し、胃を除去した。その胃に1%ホルマリン10mlを注入し、30分間固定した。ホルマリン固定後、胃を大彎に沿って切開し、その内部表面をデジタルカメラで撮影した。その後、写真上で面積測定法で(planimetrically)、胃粘膜の損傷面積を測定し、それを潰瘍指数で表した。この指数は、腺の全体面積に対する損傷部位の比率である。試験調製物の潰瘍形成抑制率(%)は、下記のようにして算出した。
Experimental example 1: Identification of anti-peptic ulcer substances present in rice extract
(1) Measurement of anti-peptic ulcer activity
Measurements were made with slight modifications to the method described in Yamasaki et al. (Eur. J. Pharmacol. 142, 23-29, 1987). Male rats (Sprague-Dawley) weighing 250 ± 20 g were orally administered with 1 ml of ethanol to induce gastric ulcer. To measure the activity of the anti-peptic ulcer preparation, 1 ml of the test preparation was orally administered 30 minutes before ethanol administration. The same amount of distilled water was administered to the control group. Rats were sacrificed under ether anesthesia 1.5 hours after ethanol administration, and the stomach was removed. 10% 1% formalin was injected into the stomach and fixed for 30 minutes. After formalin fixation, the stomach was incised along the large vagina and the inner surface was photographed with a digital camera. Thereafter, the area of damage to the gastric mucosa was measured planimetrically on the photograph and expressed as an ulcer index. This index is the ratio of the damaged site to the total area of the gland. The ulcer formation inhibition rate (%) of the test preparation was calculated as follows.

全てのデータの統計学的有意性の検証は、一元分散分析(one-way ANOVA)とシェフェの方法(Scheffe test)によって行った。   The statistical significance of all data was verified by one-way analysis of variance (one-way ANOVA) and Scheffe test.

(2) 米抽出物と他の穀物抽出物との抗消化性潰瘍活性の比較
もち米抽出物、うるち米抽出物、大麦抽出物および小麦抽出物の抗消化性潰瘍活性を比較するために、それぞれ抽出物1mlをラットに経口投与した。30分後にエタノール1mlをラットに経口投与して、胃粘膜の損傷程度を評価した。その結果は図1に示されている。各群のラットの数は6匹であり、測定値は平均±標準偏差で表した。**p<0.01は対照群と比較した場合である。
(2) Comparison of anti-peptic ulcer activity between rice extract and other cereal extracts To compare the anti-peptic ulcer activity of glutinous rice extract, glutinous rice extract, barley extract and wheat extract, respectively 1 ml of extract was orally administered to rats. After 30 minutes, 1 ml of ethanol was orally administered to rats to evaluate the degree of damage to the gastric mucosa. The result is shown in FIG. The number of rats in each group was 6, and the measured values were expressed as mean ± standard deviation. ** p <0.01 is when compared with the control group.

図1のように、もち米抽出物が最も強い抗消化性潰瘍活性を示し、うるち米抽出物も、もち米抽出物よりは低かったが、有意な抗消化性潰瘍活性を示した。しかし、大麦抽出物と小麦抽出物はどちらも、有意な抗消化性潰瘍活性を表さなかった。従って以下の実験例では、抗消化性潰瘍性物質を同定するために、主にもち米抽出物を使用した。   As shown in FIG. 1, the glutinous rice extract showed the strongest anti-peptic ulcer activity, and the glutinous rice extract also showed a significant anti-peptic ulcer activity although it was lower than the glutinous rice extract. However, neither the barley extract nor the wheat extract showed significant anti-peptic ulcer activity. Therefore, in the following experimental examples, glutinous rice extract was mainly used to identify anti-peptic ulcer substances.

(3) もち米抽出物の沈殿分画と可溶分画中の抗消化性潰瘍活性の分布
もち米抽出物の抗消化性潰瘍性物質がどの分画に存在するかを判定する第1ステップとして、実施例1および2で調製したもち米抽出物の沈殿および可溶分画をラットに経口投与した(1ml/ラット)。30分後にエタノールを経口投与して(1ml/ラット)、胃粘膜の損傷程度を評価した。結果を図2に示す。各実験群のラットの数は6匹で、測定値は平均±標準偏差で表した。p<0.05及び**p<0.01は蒸留水群と比較した場合である。††p<0.01はもち米抽出物群と比較した場合である。
(3) Distribution of anti-peptic ulcer activity in the precipitated fraction and soluble fraction of glutinous rice extract The first step to determine in which fraction the anti-peptic ulcer substance of glutinous rice extract is present As described above, the precipitate and soluble fraction of the glutinous rice extract prepared in Examples 1 and 2 were orally administered to rats (1 ml / rat). After 30 minutes, ethanol was orally administered (1 ml / rat), and the degree of damage to the gastric mucosa was evaluated. The result is shown in figure 2. The number of rats in each experimental group was 6, and the measured values were expressed as mean ± standard deviation. * P <0.05 and ** p <0.01 are when compared with the distilled water group. †† p <0.01 is when compared to the glutinous rice extract group.

図2に示すように、蒸留水投与対照群、もち米抽出物投与群、もち米抽出物沈殿分画投与群およびもち米抽出物可溶分画投与群の平均潰瘍指数は、それぞれ66.5±10.4、16.0±8.9、46.3±10.7及び61.5±11.7%で、後3者の潰瘍形成抑制率は、それぞれ75.9%、30.4%及び7.5%だった。この結果より、沈殿分画はかなりの抗消化性潰瘍活性(もち米抽出物の40%程度)を示した反面、可溶分画は有意な抗消化性潰瘍活性を示さなかったことが分かる。この結果は、抗消化性潰瘍性の主要物質が、もち米抽出物の可溶分画よりもむしろ沈殿分画に存在することを示している。さらに、前記主要物質は、最大活性のためには可溶性の活性化成分を必要とすることを示唆している。   As shown in FIG. 2, the average ulcer index of the control group administered with distilled water, the glutinous rice extract administration group, the glutinous rice extract precipitation fraction administration group and the glutinous rice extract soluble fraction administration group was 66.5 ± 10.4, respectively. 16.0 ± 8.9, 46.3 ± 10.7 and 61.5 ± 11.7%, and the ulcer formation inhibition rates of the latter three were 75.9%, 30.4% and 7.5%, respectively. From this result, it can be seen that the precipitate fraction showed considerable anti-peptic ulcer activity (about 40% of the glutinous rice extract), whereas the soluble fraction did not show significant anti-peptic ulcer activity. This result indicates that the main anti-peptic ulcerous substance is present in the precipitated fraction rather than the soluble fraction of glutinous rice extract. Furthermore, the main substance suggests that a soluble activating component is required for maximum activity.

(4) もち米抽出物沈殿分画の抗消化性潰瘍活性の、様々な物質による増強
他の穀物や天然食品の可溶分画もまたもち米抽出物沈殿分画の抗消化性潰瘍活性を増強し得るか調べるために、実施例3〜6で調製したうるち米抽出物、大麦抽出物、水参抽出物および茶抽出物の可溶分画のそれぞれを、もち米抽出物沈殿分画に添加した前後で抗消化性潰瘍活性を測定した。この実験例のために、実施例2で調製したもち米抽出物沈殿分画を遠心分離して上清を除去した。その後、前記沈殿を上記の抽出物の可溶分画のそれぞれと混合し、混合物を実験ラットに投与した。
(4) Enhancement of the anti-peptic ulcer activity of the glutinous rice extract fraction by various substances The soluble fraction of other cereals and natural foods also has the anti-peptic ulcer activity of the glutinous rice extract fraction. In order to investigate whether it can be enhanced, each of the soluble fractions of glutinous rice extract, barley extract, mizusane extract and tea extract prepared in Examples 3 to 6 was added to the glutinous rice extract precipitation fraction. Anti-peptic ulcer activity was measured before and after. For this experimental example, the glutinous rice extract precipitate fraction prepared in Example 2 was centrifuged to remove the supernatant. The precipitate was then mixed with each of the soluble fractions of the above extract and the mixture was administered to experimental rats.

表1に示した通り、うるち米や大麦抽出物などの穀物抽出物は勿論、水参抽出物および茶(緑茶、紅茶および烏龍茶)抽出物の可溶分画全てが、それら単独では有意な抗消化性潰瘍活性を表さないが、もち米抽出物沈殿分画の抗消化性潰瘍活性を増強させることができた。これらの試験した可溶分画のうち、茶抽出物が最も強い増強効果を示すことが分かった。   As shown in Table 1, not only cereal extracts such as glutinous rice and barley extract, but also all soluble fractions of sangu extract and tea (green tea, black tea and oolong tea) extract are significantly anti-digested by themselves. The anti-peptic ulcer activity of the glutinous rice extract precipitate fraction could be enhanced. Of these tested soluble fractions, tea extract was found to show the strongest enhancement effect.

表1に示された増強効果に寄与している化合物を同定するために、いくつかの候補化合物をもち米抽出物沈殿分画に添加して、抗消化性潰瘍活性の変化を測定した。   In order to identify the compounds contributing to the enhancing effects shown in Table 1, several candidate compounds were added to the glutinous rice extract precipitate fraction to measure changes in anti-peptic ulcer activity.

表2に示した通り、10mMの(‐)‐エピカテキン(EC)、タンニン酸およびシステインが、もち米抽出物沈殿分画の抗消化性潰瘍活性を著しく増強することが分かった。一方、他のアミノ酸、アスコルビン酸、還元型グルタチオン、(‐)‐エピガロカテキン没食子酸塩、フィチン酸、没食子酸およびカフェインは、10mMで有意な増強効果を示さなかった。   As shown in Table 2, 10 mM (-)-epicatechin (EC), tannic acid and cysteine were found to significantly enhance the anti-peptic ulcer activity of the glutinous rice extract precipitate fraction. On the other hand, other amino acids, ascorbic acid, reduced glutathione, (−)-epigallocatechin gallate, phytic acid, gallic acid and caffeine did not show a significant enhancing effect at 10 mM.

(5) もち米抽出物沈殿分画の抗消化性潰瘍活性に対する熱処理およびペプシン処理の効果
もち米抽出物沈殿分画を沸騰水で5分間加熱処理するか、又は1%の乳酸存在下に0.1mg/mlペプシンと37℃で1時間反応させた。その後、それぞれの処理物を2mg/mlの緑茶抽出物と混合し、ラットに投与して抗消化性潰瘍活性を測定した。その結果は図3に示されている。各群のラットの数は6匹で、測定値は平均±標準偏差で表した。**p<0.01は蒸留水群と比較した場合である。††p<0.01は無処理の群と比較した場合である。
(5) Effect of heat treatment and pepsin treatment on the anti-peptic ulcer activity of the glutinous rice extract fraction Fraction of the glutinous rice extract fraction with boiling water for 5 minutes or 0.1% in the presence of 1% lactic acid The mixture was reacted with mg / ml pepsin at 37 ° C for 1 hour. Thereafter, each treated product was mixed with 2 mg / ml green tea extract and administered to rats to measure anti-peptic ulcer activity. The result is shown in FIG. The number of rats in each group was 6, and the measured values were expressed as mean ± standard deviation. ** p <0.01 is when compared with the distilled water group. †† p <0.01 is compared to the untreated group.

図3に示されるように、もち米抽出物沈殿分画を熱処理するか、ペプシンで処理すると、その分画の抗消化性潰瘍活性が完全に喪失された。もち米抽出物沈殿分画を、ペプシンなしで1%乳酸と反応させたとき初めて、活性が維持された。これらの結果は、もち米抽出物沈殿分画中の抗消化性潰瘍活性を示す物質が、蛋白質であり得ることを示唆するものである。   As shown in FIG. 3, when the glutinous rice extract precipitate fraction was heat-treated or treated with pepsin, the anti-peptic ulcer activity of the fraction was completely lost. The activity was maintained only when the glutinous rice extract fraction was reacted with 1% lactic acid without pepsin. These results suggest that the substance exhibiting anti-peptic ulcer activity in the glutinous rice extract precipitate fraction may be a protein.

(6) もち米抽出物沈殿分画中のグロブリン、グルテリン及びプロラミン蛋白質間の抗消化性潰瘍活性の比較
もち米抽出物沈殿分画中に存在するグロブリン、グルテリン及びプロラミン蛋白質のいずれが抗消化性潰瘍活性を示すか調べるために、沈殿分画をそれぞれ0.5M NaCl、1%乳酸および70%エタノールで4時間抽出し、3,000×gで10分間遠心分離した。その後、可溶化亜分画について蒸留水にて24時間透析した後に抗消化性潰瘍活性を測定し、残渣沈殿亜分画について、沈殿物を蒸留水で懸濁して活性を測定した(図4)。抗消化性潰瘍活性を測定するために、亜分画に2mg/mlの緑茶抽出物を活性化剤として添加した。各群のラットの数は6匹で、測定値は平均±標準偏差で表した。p<0.05及び**p<0.01は蒸留水群と比較した場合である。††p<0.01は無処理の沈殿分画群と比較した場合である。
(6) Comparison of anti-digestible ulcer activity between globulin, glutelin and prolamin protein in glutinous rice extract precipitate fraction Any of globulin, glutelin and prolamin protein present in glutinous rice extract fraction is anti-digestible In order to examine whether ulcer activity was exhibited, the precipitate fractions were extracted with 0.5 M NaCl, 1% lactic acid and 70% ethanol for 4 hours, respectively, and centrifuged at 3,000 × g for 10 minutes. Thereafter, the anti-peptic ulcer activity was measured after dialyzing with distilled water for 24 hours for the solubilized subfraction, and the activity was measured by suspending the precipitate with distilled water for the residual sediment subfraction (FIG. 4). . To measure anti-peptic ulcer activity, 2 mg / ml green tea extract was added as an activator to the subfraction. The number of rats in each group was 6, and the measured values were expressed as mean ± standard deviation. * P <0.05 and ** p <0.01 are when compared with the distilled water group. †† p <0.01 is when compared with the untreated precipitate fraction group.

図4に示すように、0.5M NaCl又は1%乳酸で抽出した後は、抗消化性潰瘍活性の大部分が沈殿分画に残っていた。しかし、70%エタノールで抽出すると抗消化性潰瘍活性の全てが消失した。かわりに、70%エタノール抽出物の可溶化亜分画は強力な抗消化性潰瘍活性を示した。   As shown in FIG. 4, most of the anti-peptic ulcer activity remained in the precipitate fraction after extraction with 0.5M NaCl or 1% lactic acid. However, extraction with 70% ethanol lost all anti-peptic ulcer activity. Instead, the solubilized subfraction of 70% ethanol extract showed strong anti-peptic ulcer activity.

以上の結果は、プロラミンがもち米抽出物沈殿分画の抗消化性潰瘍活性を示すことを強く示唆するものである。   The above results strongly suggest that prolamin exhibits the anti-peptic ulcer activity of the glutinous rice extract precipitate fraction.

(7) 精製したもち米プロラミンの抗消化性潰瘍活性
もち米プロラミンの抗消化性潰瘍活性を確認するために、実施例7のようにもち米粉末からプロラミンを精製した。その後、まず精製した蛋白質をラエムリ(Laemmli)の方法(Nature 192, 680-682, 1970)に従いSDS-PAGEで分析して純度を評価した。図5は、15%ポリアクリルアミドゲルに10-30μgの蛋白質を加えて行ったSDS-PAGE分析の結果を示す。当該分析において、分子量が約13KDaの単一ポリペプチドバンドが検出された。この結果は、米プロラミンの特性に関する先の報告と一致する。よって、実施例7でもち米から調製したタンパク質は、高度に精製されたプロラミン蛋白質であることが示される。
(7) Anti-peptic ulcer activity of purified glutinous rice prolamin To confirm the anti-peptic ulcer activity of glutinous rice prolamin, prolamin was purified from glutinous rice powder as in Example 7. Thereafter, the purified protein was first analyzed by SDS-PAGE according to the method of Laemmli (Nature 192, 680-682, 1970) to evaluate the purity. FIG. 5 shows the results of SDS-PAGE analysis performed by adding 10-30 μg of protein to a 15% polyacrylamide gel. In the analysis, a single polypeptide band having a molecular weight of about 13 KDa was detected. This result is consistent with previous reports on the characteristics of rice prolamin. Therefore, it is shown that the protein prepared from glutinous rice in Example 7 is a highly purified prolamin protein.

次に、もち米プロラミンの抗消化性潰瘍活性を用量依存的に測定した(図6)。この実験では、活性化剤として10mMのエピカテキン(EC)を添加した。各群のラットの数は6匹で、測定値は平均±標準偏差で表した。p<0.05及び**p<0.01は蒸留水投与対照群と比較した場合である。 Next, the anti-peptic ulcer activity of glutinous rice prolamin was measured in a dose-dependent manner (FIG. 6). In this experiment, 10 mM epicatechin (EC) was added as an activator. The number of rats in each group was 6, and the measured values were expressed as mean ± standard deviation. * P <0.05 and ** p <0.01 are compared with the control group administered with distilled water.

図6に示されるように、プロラミンの用量が増えるにつれて連続的に、抗消化性潰瘍活性が上昇した。体重Kg当り0.3mgの用量で、プロラミンは有意な抗消化性潰瘍活性を示し始め、用量が体重Kg当り3mgのときに、活性が最高値に達した。   As shown in FIG. 6, the anti-peptic ulcer activity continuously increased as the prolamin dose increased. At a dose of 0.3 mg / kg body weight, prolamin began to show significant anti-peptic ulcer activity, reaching a maximum when the dose was 3 mg / kg body weight.

(8) 精製したうるち米プロラミンの抗消化性潰瘍活性
うるち米抽出物も有意な抗消化性潰瘍活性を示したため(図1)、(7)と同様の方法で、うるち米から精製したプロラミンの抗消化性潰瘍活性を調べた。うるち米から得たプロラミン調製物をSDS-PAGE分析したところ、13KDaの単一ポリペプチドバンドが検出され(図7)、これは調製した蛋白質が高度に精製されたプロラミンであることを示す。
(8) Anti-peptic ulcer activity of purified glutinous rice prolamin Since glutinous rice extract also showed significant anti-peptic ulcer activity (Fig. 1), the anti-digestibility of prolamin purified from glutinous rice in the same manner as (7) The ulcer activity was examined. SDS-PAGE analysis of a prolamin preparation obtained from glutinous rice detected a single polypeptide band of 13 KDa (FIG. 7), indicating that the prepared protein is highly purified prolamin.

また、精製したうるち米プロラミンは、用量依存的な抗消化性潰瘍活性を示した(図8)。しかし、もち米プロラミンに比べてその比活性は遥かに低かった。   Purified glutinous rice prolamin exhibited a dose-dependent anti-peptic ulcer activity (FIG. 8). However, its specific activity was much lower than glutinous rice prolamin.

Claims (5)

米プロラミンを活性成分として含むことを特徴とする抗消化性潰瘍組成物。   An anti-peptic ulcer composition comprising rice prolamin as an active ingredient. 茶抽出物、水参抽出物、大麦抽出物、(‐)‐エピカテキン(EC)、タンニン酸およびシステインからなる群より選択される少なくとも1種を、抗消化性潰瘍活性促進用の補助成分として更に含むことを特徴とする、請求項1に記載の抗消化性潰瘍組成物。   At least one selected from the group consisting of tea extract, water extract, barley extract, (-)-epicatechin (EC), tannic acid and cysteine as an auxiliary component for promoting anti-peptic ulcer activity 2. The anti-peptic ulcer composition according to claim 1, further comprising: 前記米プロラミン1重量部に対して、前記補助成分を1〜80重量部含むことを特徴とする、請求項2に記載の抗消化性潰瘍組成物。   3. The anti-peptic ulcer composition according to claim 2, comprising 1 to 80 parts by weight of the auxiliary component with respect to 1 part by weight of the rice prolamin. 前記米がもち米またはうるち米である、請求項1に記載の抗消化性潰瘍組成物。   2. The anti-peptic ulcer composition according to claim 1, wherein the rice is glutinous rice or glutinous rice. 経口投与用製剤に製剤化されることを特徴とする、請求項1に記載の抗消化性潰瘍組成物。   2. The anti-peptic ulcer composition according to claim 1, which is formulated into a preparation for oral administration.
JP2011502850A 2008-04-02 2009-03-26 Anti-peptic ulcer composition containing rice prolamin Pending JP2011516467A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR10-2008-0030917 2008-04-02
KR1020080030917A KR100963339B1 (en) 2008-04-02 2008-04-02 Anti-peptic ulcer preparation comprising rice prolamin
PCT/KR2009/001544 WO2009145424A2 (en) 2008-04-02 2009-03-26 Anti-peptic ulcer composition comprising rice prolamin

Publications (1)

Publication Number Publication Date
JP2011516467A true JP2011516467A (en) 2011-05-26

Family

ID=41377699

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011502850A Pending JP2011516467A (en) 2008-04-02 2009-03-26 Anti-peptic ulcer composition containing rice prolamin

Country Status (4)

Country Link
JP (1) JP2011516467A (en)
KR (1) KR100963339B1 (en)
CN (1) CN101983053B (en)
WO (1) WO2009145424A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178245A1 (en) * 2013-04-30 2014-11-06 株式会社サタケ Method for collecting protein contained in rice and protein obtained by said method

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101336411B1 (en) * 2011-05-27 2013-12-04 한국식품연구원 Novel use of rice extract for improving, preventing or treating sleep disorders, anxiety, or depression
CN102335414B (en) * 2011-09-30 2013-07-03 哈尔滨工业大学 Preparation method of rice prolamin bile acid adsorbent
KR20160017607A (en) * 2014-08-05 2016-02-16 전남대학교산학협력단 Oral anti-atopic preparations comprising rice prolamin

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04210645A (en) * 1990-12-11 1992-07-31 Soken:Kk Antiulcer agent
KR20010019384A (en) * 1999-08-26 2001-03-15 안봉환 A herbal preparation with anti-ulcer activity composed of glutinous rice and tea extracts
JP2007068454A (en) * 2005-09-06 2007-03-22 Kizakura Co Ltd Method for producing rice protein, rice protein produced by the method, and food

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100253740B1 (en) 1996-10-23 2000-04-15 Lee Min Hwa A beverage for prevention of ulcer comprising glutinous rice extracts
KR100810110B1 (en) * 2001-10-25 2008-03-06 전남대학교산학협력단 Preparation of transparent liquid composition with anti-ulcer activity comprising extracts of glutinous rice and raw ginseng, and process for the preparation thereof
KR20050122581A (en) * 2004-06-25 2005-12-29 안봉환 Preparation of transparent liquid composition with anti-ulcer activity comprising glutinous rice extract
KR100821943B1 (en) * 2007-03-27 2008-04-15 다산엠앤에프(주) Clear liquid anti-ulcer preparations made of glutinous rice and tea extracts

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04210645A (en) * 1990-12-11 1992-07-31 Soken:Kk Antiulcer agent
KR20010019384A (en) * 1999-08-26 2001-03-15 안봉환 A herbal preparation with anti-ulcer activity composed of glutinous rice and tea extracts
JP2007068454A (en) * 2005-09-06 2007-03-22 Kizakura Co Ltd Method for producing rice protein, rice protein produced by the method, and food

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013025386; 日本土壌肥料学雑誌,1996,Vol.67,No.2,139-146 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014178245A1 (en) * 2013-04-30 2014-11-06 株式会社サタケ Method for collecting protein contained in rice and protein obtained by said method
JP2014214145A (en) * 2013-04-30 2014-11-17 株式会社サタケ Method for collecting protein contained in rice and protein obtained thereby

Also Published As

Publication number Publication date
CN101983053A (en) 2011-03-02
WO2009145424A2 (en) 2009-12-03
CN101983053B (en) 2012-10-10
KR20090105460A (en) 2009-10-07
WO2009145424A3 (en) 2010-01-21
KR100963339B1 (en) 2010-06-14

Similar Documents

Publication Publication Date Title
KR20110027717A (en) Composition comprising 1,3/1,6 beta glucan for reducing weight
AU2009200893A1 (en) Compositions for therapeutic use comprising a vitamin, a metal salt and insulin or a growth hormone
JP2011516467A (en) Anti-peptic ulcer composition containing rice prolamin
KR20130035091A (en) Composition for preventing and treating varicocele or male infertility comprising anthocyanin extracted from black soybean
JP2003040787A (en) Composition having physiological activity and method for producing the same
CN111265650A (en) Novel traditional Chinese medicine composition and preparation method thereof
JP7020915B2 (en) Soluble and stable pharmaceutical compositions that are anti-inflammatory, proliferative, protective and mucosal adherent, their use and acquisition methods for treating the condition of mucosal sites, and basic pharmaceutical compositions for the preparation of pharmaceutical compositions. Things and how to get them
CN101744815B (en) Composite medicament of omeprazole sodium
JP6980791B2 (en) Composition for the prevention or treatment of gastritis or gastric ulcer
KR101708843B1 (en) Alpha-glucosidase inhibitor including extract of cinnamon and loqauts leaves
CN114392337B (en) Composition with auxiliary protection function on gastric mucosa injury and application thereof
KR100945960B1 (en) A composition containing Arazyme for the prevention and treatment of arthritis
CN111920908B (en) Pharmaceutical composition for treating peptic ulcer
CN114652812A (en) Composition for treating alcoholic gastric injury and gastric ulcer and preparation method and application thereof
KR100627820B1 (en) A herbal preparation with anti-ulcer activity composed of glutinous rice and tea extracts
KR20020064471A (en) Manufacturing method of pine charcoal and novel use thereof as an anticancer agent
KR102142342B1 (en) Pharmaceutical composition for arthritis
Adugba et al. Moringa oleifera causes gastro protection on acid-alcohol induced ulcer
Eluka et al. Anti-ulcerogenic and antioxidant properties of the aqueous leaf extract of Ficus capensis in Wistar albino rats
KR100821943B1 (en) Clear liquid anti-ulcer preparations made of glutinous rice and tea extracts
EP2556836A1 (en) Traditional chinese medicine composition for treating gastric ulcer and preparation method thereof
KR20130030620A (en) Composition for preventing and treating of pulmonary emphysema and pulmonary hypertension, comprising an extract of alismatis rhizoma as an effective component
JP4381585B2 (en) Pharmaceutical composition
KR102268670B1 (en) Pharmaceutical compositions for preventing or improving obesity and overweight, and method for manufacturing the same
KR102202122B1 (en) Composition for anti-tussive activity or discharge of phlegm activity comprising extract of Atractylodes Rhizome White and Schizandra Fruit

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20120119

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130528

A521 Written amendment

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20130820

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130917

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20140304